ATNX News and Press, Athenex Inc. From 08/05/22

Buying Penny Stocks on August 5th? Here’s What You Need to Know With another week of trading penny stocks coming to an end, there is a lot that investors need to know. Already in August, we have seen a major amount of movement across the board with both penny stocks and blue ch...

The shares of Athenex Inc. ( NASDAQ: ATNX ) climbed ~70% on rising volumes in the post-market Thursday in reaction to reports that India’s Dr Reddy's Laboratories ( RDY ) and Intas Pharmaceuticals are in talks to acquire the cancer-focused biotech. The compa...

Athenex, Inc. (ATNX) Q2 2022 Earnings Conference Call July 28, 2022 08:00 ET Company Participants Caileigh Dougherty - Director, Investor Relations Johnson Lau - Chief Executive Officer Dan Lang - President, Athenex Cell Therapy Darrel Cohen - Chief Medical O...

Athenex press release ( NASDAQ: ATNX ): Q2 GAAP EPS of -$0.28 misses by $0.13 . Revenue of $25.79M (+17.7% Y/Y) misses by $5.47M . Shares +5% PM. Athenex continues to expect product sales from continuing operations growth to be in the range of 20-25% ov...

Reports 2Q product sales of $25.8 million, up 26% year-over-year Raised $85 million in total transaction value in 2Q for total of $125 million in proceeds from sales of non-core assets in 1H 2022, and reduced Senior Credit Facility balance from $150 million to $57.5 million ...

Athenex ( NASDAQ: ATNX ) is scheduled to announce Q2 earnings results on Thursday, July 28th, before market open. The consensus EPS Estimate is -$0.20 (+39.4% Y/Y) and the consensus Revenue Estimate is $31.26M (+42.6% Y/Y). Over the last 1 year, ATNX has beaten EPS e...

BUFFALO, N.Y., July 25, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the publication of their m...

BUFFALO, N.Y., July 21, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide...

Athenex ( NASDAQ: ATNX ) and certain affiliates to sell all of its equity interests in its China subsidiaries, which are primarily engaged in Active Pharmaceutical Ingredient (API) manufacturing operations, to TiHe Capital Co., Ltd. for RMB 124.4 million, or ~$19M. Athenex wil...

Expected sale proceeds of approximately $19.0 million Company continues to monetize non-core assets to extend cash runway Proceeds from the deal will be used to pay down debt and fund operations BUFFALO, N.Y., July 11, 2022 (GLOBE NEWSWIRE) -- Athenex, In...